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Abstract
Background: A 40-bp variable number of tandem repeats (VNTR) polymorphism exists in the
15th exon of DAT1, the gene encoding the human dopamine transporter (DAT). Though the VNTR
resides in a region encoding the 3' untranslated region (UTR) and does not alter the protein's
amino acid sequence, the prevalent 10-repeat variant has shown both linkage and association to
Attention Deficit Hyperactivity Disorder (ADHD). In this study, we examined the effects of the
DAT1 VNTR on measures of in vitro DAT expression and pharmacology. A series of four DAT1
constructs, each containing the DAT1 coding region, but varying with respect to the downstream
presence or content of the 3'UTR, were engineered and stably transfected into an HEK-293 variant
using Flp-In integration, an enzyme-mediated, site-specific recombination technology.
Results: [3H] Win 35,428 saturation binding assays and DAT immunoblots revealed statistically
significant differences in DAT expression attributable to DAT1 genotype. Cells harboring the 10-
repeat DAT1 variant were characterized by a Bmax approximately 50% greater than cells with the 9-
repeat VNTR; those containing only the DAT1 coding region or the coding region flanked by a
truncated 3' UTR resulted in greater DAT density than either of the naturalistic 9- and 10-repeat
variants. Competition binding assays showed no statistically significant DAT1 genotype effects on
the DAT affinity for methylphenidate, a finding consistent with the positional location of the VNTR.
Conclusion: This study identified the DAT1 VNTR as a functional polymorphism and provides an
interpretive framework for its association with behavioral phenotypes.
Background
The human dopamine transporter (hDAT), one member
of a family of Na+/Cl- dependent transmembrane trans-
port proteins, serves as a critical regulator of dopaminergic
neurotransmission throughout much of the brain. The
~64 kb DAT1  gene (SLC6A3) that encodes the DAT
includes 15 exons separated by 14 introns [1]. Concurrent
with the cloning and chromosomal mapping of DAT1 to
the short arm of chromosome 5 [2], a VNTR polymor-
phism was identified in the 15th exon, a region encoding
the transcript's 3' UTR [3,4]. The 40-bp VNTR element is
repeated between 3–13 times and in most human popu-
lations occurs with greatest frequency in the 9- and 10-
repeat forms [5-7]. This polymorphic variation may be
evolutionarily young, as a VNTR homologue has been
observed in humans, chimpanzees, and cynomologus
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macaques, but not in lower mammals including the rat
and mouse [8-10]. Though the VNTR resides in the 3'UTR
and therefore does not affect the protein's amino acid
sequence, regulatory factors such as mRNA stability and
nuclear transport, and protein synthesis are potentially
regulated by such variations [11-14].
Given the prominent role of dopamine neurotransmis-
sion in normal and abnormal behaviors, the DAT1 VNTR
became the object of numerous genetic linkage and asso-
ciation studies [15-20], in vitro reporter gene experiments
[21-26], in vivo SPECT molecular imaging studies [27-30],
and pharmacogenetic examinations of the well-docu-
mented inter-individual variation in the response to treat-
ment with DAT inhibitors [31-34]. Reports of the
association of the DAT1 VNTR with ADHD have garnered
particular attention, with the balance of evidence relating
the 10-repeat VNTR to symptoms of the disorder [35].
Despite its high frequency in the general population [7]
and an absence of studies addressing possible effects of
the VNTR on measures of DAT physiology and pharma-
cology, the 10-repeat DAT1 allele has become generally
recognized as a "high risk" allele for ADHD.
The present study utilized radioligand binding and immu-
noblotting techniques to compare in vitro DAT density
and ligand affinity across a series of cell lines stably trans-
fected with constructs containing the DAT1 coding region
flanked downstream by one of four DAT1 3'UTR variants.
Flp-mediated recombination, one of a family of site-spe-
Summary of DAT1 constructs used in Flp-In recombination protocol Figure 1
Summary of DAT1 constructs used in Flp-In recombination protocol. Top left: hDAT, DAT1 coding region necessary and suffi-
cient to produce a functional transporter protein. Top right: hDAT Zero, a construct containing the DAT1 coding region 
flanked by an ~800 bp fragment of the 3'UTR upstream of the VNTR region. Bottom left: hDAT 9, a construct with the DAT1 
coding region upstream of a full length 3'UTR harboring the 9-repeat VNTR. Bottom right: hDAT 10, a construct with the 
DAT1 coding region upstream of a full length 3'UTR containing the 10-repeat VNTR.BMC Genetics 2005, 6:55 http://www.biomedcentral.com/1471-2156/6/55
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cific recombination technologies, was used to integrate
the DAT1 constructs into a common, transcriptionally-
active region of the genome, eliminating several caveats
associated with traditional reporter gene methodologies
[36]. Flp recombinase, the enzymatic basis of the system,
is a Saccharomyces cerevisiae derived enzyme that utilizes a
substrate Flp recombination target (FRT) sequence
upstream of a gene of interest (GOI) to site-specifically
insert the GOI into a target site in a host cell line, thereby
providing a well-controlled approach to establishing the
in vitro functional effect of the DAT1 VNTR polymorphism
on the DAT [37].
Results
DAT binding assays
Results of three independent [3H] Win 35,428 saturation
binding experiments revealed statistically significant (p <
0.05) differences in Bmax attributable to DAT1 VNTR gen-
otype (Figure 2). Membranes from cells stably transfected
with the DAT1 coding region (hDAT) displayed the high-
est mean Bmax. Extension of hDAT with the most proximal
~800 bp of the DAT1 3'UTR (hDAT Zero) was associated
with decreased in vitro DAT density compared to the hDAT
line. Of the two prevalent DAT1 VNTR variants (hDAT 9
and hDAT 10), cells stably transfected with construct har-
boring the 10-repeat allele displayed a mean Bmax 54%
greater than those harboring the 9-repeat variant. Statisti-
cally significant differences in Kd were observed between
DAT1 variants in saturation binding assays, though the
magnitude of the effect was modest and considered phys-
iologically insignificant (Figure 3); goodness of fit (R2)
exceeded 0.98 for all non-linear regressions. Three inde-
pendent competition binding experiments also revealed
no pharmacologically significant effects of DAT1 geno-
type on methylphenidate's ability to displace [3H] Win
35,428 from the DAT (Figure 4). R2 values were ≥ 0.95 for
all competition binding curves.
DAT western blots
The observed rank order of immunoblotted DAT signal
intensity across three independent replicates paralleled
that of Bmax values derived from saturation binding exper-
iments for the four different DAT1 constructs (Figure 5).
Mock transfected cells displayed no DAT immunoreactiv-
ity. Uniformity of 14-3-3β immunoreactivity between the
different transfected cell lines confirmed near equivalent
between-lane protein loading and served as a basis for
normalization. Significant differences (p < 0.05) were
detected for all comparisons except hDAT 10-vs-hDAT
Zero.
Discussion
The VNTR polymorphism of DAT1, though residing out-
side the gene's coding region, is of interest due to its pos-
sible influence on the regulation of dopaminergic
neurotransmission, its implication in conferring genetic
vulnerability for ADHD, and its putative role in modulat-
ing response to treatment with a first line medication,
methylphenidate. The VNTR has not, however, been char-
acterized as regards its possible influence on DAT physiol-
ogy and pharmacology. Accumulating evidence that the
3'UTR influences the nuclear export, polyadenylation,
subcellular targeting and rates of transcription and degra-
dation of mRNA [11] supports the possibility that a VNTR
polymorphism in this region could exert a regulatory
influence on gene function. Observed DAT1 VNTR effects
on reporter gene expression have provided initial support
for an effect of the VNTR on in vitro gene expression [21-
26], though the results vary widely (see [25] for discus-
sion). Furthermore, heterologous reporter gene method-
ologies are subject to context-specific effects that may not
reflect a sequence's impact on a gene of interest [38]. The
Comparative influence of 3'UTR variation on DAT saturation  binding across three independent replicates Figure 2
Comparative influence of 3'UTR variation on DAT saturation 
binding across three independent replicates. A) A character-
istic binding curve revealing differences in Bmax attributable to 
DAT1 genotype. Mock-transfected negative control cells dis-
played no specific DAT binding. B) A one way ANOVA with 
Holm-Sidak post-hoc analysis demonstrated genotype-
dependent differences in DAT density for all multiple com-
parisons (* = p < 0.05).
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present study provides multiple lines of converging in vitro
evidence for the DAT1 VNTR's modulatory effect on DAT
expression, thus supporting it as a functional polymor-
phism that may contribute to the recognized inter-indi-
vidual differences in DAT density and dopaminergic
function.
The hDAT cell line, which lacks a 3'UTR altogether, dis-
played the highest overall DAT density and immunoreac-
tivity, with a Bmax for [3H] Win 35,428 binding roughly
2.5-fold that of the hDAT 9 line. The hDAT Zero cell line
had a Bmax for [3H] Win 35,428 binding ~25% less than
that of the hDAT construct, a result that implicates the first
~800 bp of the DAT1 3'UTR in diminishing DAT1 tran-
scription, mRNA stability, or translation. The additional
extension of the 3'UTR to include either the 9 or 10 repeat
variant further attenuated Bmax and DAT immunoreactiv-
ity compared to that for the hDAT and hDAT Zero cell
lines. These results are consistent with the results of
reporter gene assays [13,25] in which constructs contain-
ing the VNTR polymorphism were associated with
decreased DAT1 expression. Incremental attenuation of
DAT density by both the ~800 bp fragment and the VNTR
region suggests the presence of at least two regulatory
regions in the DAT1 15th exon, with the differential effects
of the 9- and 10-repeat variants possibly due to interac-
tions between a VNTR-specific attenuator and one con-
tained within the ~800 bp fragment.
Comparison of the 9- and 10-repeat variants, the two
most frequent allelic variations of DAT1 [5,7] revealed
that DAT binding site density for the 10-repeat VNTR was
elevated approximately 50% over that of the 9-repeat
allele, with western analysis confirming this finding. This
result indicates that the 3'UTR does not simply mediate a
length-dependent reduction in DAT availability, as has
been previously suggested [22]. Rather, variation in the
number of tandem repeats appears to have distinct mod-
ulatory influences on in vitro DAT density.
At least five groups have reported in vitro reporter gene
results examining the relative effects of the DAT1 9- and
10-repeat VNTR's influence on luciferase or GFP expres-
sion in transiently transfected systems. Fuke and cowork-
ers compared the impact of DAT1 3'UTRs containing the
7-, 9- and 10-repeat alleles on luciferase reporter activity
[21]. Their results suggested that the 10-repeat allele
yielded the greatest reporter gene expression. Addition-
ally, it was found that constructs harboring the VNTR pol-
ymorphism (of any variety) resulted in lower reporter
gene expression than those with no repeat region; our data
largely concurs with these observations. However, Inoue-
Murayama and colleagues [22], who assessed the relative
luciferase activities associated with the human 9-, 10- and
11-repeat alleles in addition to several non-human pri-
mate  DAT1  VNTRs, reported an inverse relationship
between reporter gene activity and repeat number, an
observation consistent with possible length-dependent
reductions in transfection efficiency, and a finding that
differs from our data. Miller and Madras [26] arrived at
similar findings (i.e. 9 > 10), though their analysis sug-
gested that an additional SNP located in the 3'UTR may
further regulate the VNTR's effects. Lastly, Mill [25], who
recently published a well-controlled set of reporter gene
analyses using both neuronal and non-neuronal cell lines,
found no significant difference in reporter gene activity
attributable to VNTR copy number. These discrepant stud-
ies underscore the need to examine the DAT1 VNTR effects
under carefully controlled experimental conditions using
the DAT protein itself as the reporter signal.
The veracity of our findings is reinforced by the use of a
targeted stable integration protocol that eliminates con-
founds to construct comparison attributable to variable
transfection efficiency or clonal variance, both common
pitfalls of transient transfection or conventional non-tar-
geted stable integration approaches. Unlike typical stable
integration methods, the enzymatically-mediated Flp-In
system employed herein resulted in DAT-expressing cell
lines with their respective constructs directionally inte-
grated at a common, transcriptionally-active locus [39-
41]. pcDNA5/FRT's hygromycin resistance gene, which
was used in the isolation and expansion of cell lines for
this study, lacks both a promoter and start codon, thereby
preventing selection in instances of random genomic
insertion. When enzymatically integrated into the host
Mean Kd measurements derived from three independent [3H]  Win 35,428 saturation binding assays Figure 3
Mean Kd measurements derived from three independent [3H] 
Win 35,428 saturation binding assays. A one way ANOVA 
with Holm-Sidak post-hoc analysis detected VNTR-depend-
ent differences in the DAT ligand affinity (* = p < 0.05) for all 
but the hDAT-vs-hDAT9 compairson.
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cell line, however, the gene becomes properly aligned
with both a promoter and initiation sequence, permitting
expression of the hygromycin resistance gene and DAT1
variant from a common site. This targeted stable integra-
tion approach eliminates the need to normalize data to
account for differential transfection efficiency, a signifi-
cant confound of most traditional reporter gene method-
ologies.
The current findings are particularly interesting consider-
ing the divergent results of four in vivo human [123I] β-CIT
SPECT studies examining the impact of the DAT1 VNTR
polymorphism on measures of striatal DAT binding
potential [27-30]. The first study, conducted in a mixed
population of abstinent alcoholics and healthy controls,
found that 10-repeat homozygotes displayed a 22%
higher DAT binding density than 9/10 heterozygotes [29].
A similar study conducted in a population of healthy sub-
jects revealed sharply different results, with 10-repeat
homozygotes characterized by striatal DAT binding
13.4% lower than subjects carrying a 9-repeat allele [28];
van Dyck [30] recently arrived at similar findings. Mar-
tinez [27], also utilizing [123I] β-CIT, studied a mixed pop-
ulation of 59 healthy controls and schizophrenics and
found no difference in binding potential between 10-
repeat homozygotes and carriers of the 9-repeat allele.
Though these studies differ widely in their conclusions, a
number of factors may have contributed to the varied
results. Foremost, subject populations varied from
healthy individuals to those with psychiatric diagnoses
characterized by probable dopaminergic dysregulation.
Second, the use of [123I] β-CIT, a high affinity DAT ligand,
but one lacking selectivity for the DAT over the serotonin
transporter, highlights the need to conduct experiments
using more selective ligands, preferably in a PET setting
[42,43]. Third, two of these studies focused exclusively on
the  DAT1  VNTR polymorphism and did not consider
other polymorphisms capable of modulating [123I] β-CIT
binding (e.g. SERT promoter VNTR polymorphism
known to modulate 5-HT transporter density [44]); given
[123I] β-CIT's binding profile and the partially overlapping
brain regional distribution of DAT and SERT, a portion of
the between-study variance may be attributable to varia-
tions in genes encoding other monoamine transporters.
In light of these limitations, PET imaging with highly
selective DAT ligands [45] remains the best in vivo
approach to assessing whether the observed in vitro effects
of the DAT1 VNTR on DAT expression generalizes to the
in situ DAT.
Of interest are the small, though statistically significant,
effects of 3'UTR variations on DAT affinity for [3H] Win
35,428. Given the location of the VNTR polymorphism,
genotype-dependent variations in the DAT affinity would
not be predicted. Preliminary data from our laboratory
suggests that VNTR-dependent rates of DAT protein glyco-
sylation may account for the observed variance in ligand
affinity, a hypothesis subject to ongoing testing in our lab-
oratory.
While the present study provides evidence supporting the
DAT1 VNTR as a functional polymorphism, the strength
of this assertion is tempered by the inherent limitations of
the experimental approach. First, despite the magnitude
and reproducibility of the observed effects in the present
in vitro study, these effects may not generalize to the in vivo
condition. The association of the 10-repeat allele with an
increase in the amount of in vitro DAT protein could be
attenuated by in vivo counter-regulatory mechanisms
including upregulation of lysosomal DAT targeting and
modulation in rates of endosome-mediated DAT internal-
ization [46-48]. The current experiments, conducted in
membrane homogenates, do not discriminate between
DAT proteins functionally inserted into the cell mem-
brane and those contained within cellular vesicles. Sec-
ondly, the scope of the present study was limited to the
effects of the VNTR region independent of other SNP or
haplotype effects that may contribute to variability in
dopaminergic function; our experiments, by design, do
not reflect the recognized complexity of interactions
affecting DAT1 expression [17,24]. Third, our experiments
utilized the powerful CMV promoter; while the use of
strong viral promoters is common in experiments such as
this, possible promoter/VNTR interactions have been sug-
Representative Competition Binding Curves Figure 4
Representative Competition Binding Curves. No pharmaco-
logically significant differences exist between DAT1 variants in 
the encoded protein's affinity for methylphenidate.BMC Genetics 2005, 6:55 http://www.biomedcentral.com/1471-2156/6/55
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gested [26]. Therefore, different effects may be observed if
the CMV promoter was substituted with either the native
DAT1  promoter or a weaker constitutively active
sequence. Lastly, our results are limited to the effects of
the DAT1 VNTR in Flp-In 293 cells, a cell line that may
lack certain tissue-specific regulatory factors found in DAT
rich tissues. While it would be of interest to study these
effects in dopaminergic neurons in combination with Flp-
In integration, such an approach would render it difficult
to pharmacologically distinguish between native and
transfected DAT and would significantly compromise the
otherwise high degree of experimental control characteris-
tic of the present experiments.
Though the DAT1 3'UTR is lengthier than the transcript's
entire coding region, is a likely target for modulating
DAT1 translation, and has been associated with symp-
toms of ADHD, there exists the possibility of linkage dis-
equilibrium between the DAT1 3'UTR and a separate, yet
unidentified, causal genetic element. Still, these findings
have interpretive significance to the often-observed asso-
ciation of the 10-repeat DAT1 VNTR with ADHD. ADHD
is viewed as being related to a deficit in synaptic
dopamine subserving task-specific signaling. An increase
in DAT expression in 10-allele carriers could result in such
a dopamine deficit state, depleting dopamine's ability to
task-specifically increase signal to noise ratios in target
neurons [49,50] and result in deficits in attention and
impulse control.
Methods
Cloning of DAT1 variants
Four  DAT1  constructs were created, each containing a
common promoter, coding region, and poly (A) tail, but
varying with respect to the presence and length of the
3'UTR. All constructs were restriction mapped and
sequence verified throughout the length of the insert prior
to targeted stable transfection in Flp-In 293 cells. Though
the sequence of these clones is nearly indistinguishable
from that predicted by public genomic databases, they are
Results of western analysis support the rank order of DAT density observed in saturation binding experiments Figure 5
Results of western analysis support the rank order of DAT density observed in saturation binding experiments. A) Lane 1: 
molecular weight marker, Lane 2: negative control, Lane 3: hDAT transfected cell line, Lane 4: hDAT Zero transfected cell line, 
Lane 5: hDAT 9 transfected cell line, Lane 6: hDAT 10 transfected cell line. Blots were probed both with a rat anti-DAT mon-
oclonal antibody specific for the transporter's N-terminal region as well as a 14-3-3β polyclonal antibody to control for possi-
ble protein loading differences. DAT immunoreactivity was detected with an Alexa Fluor 680 conjugated anti-rat IgG (red) and 
14-3-3β immunoreactivity with an IRDye-800 conjugated anti-rabbit IgG (green). B) DAT immunoreactivity was normalized to 
the 14-3-3β signal, densiometrically quantified with respect 14-3-3β content, and analyzed via a one way ANOVA with a Holm-
Sidak post-hoc analysis. Statistically significant differences (* = p < 0.05) were detected for all comparisons except the 
hDAT10-vs-hDAT Zero comparison.
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not eligible for Genbank submission due to the mixed ori-
gin (cDNA and genomic DNA) of the constructs. Since the
sequence variance in and around DAT1 is complex, we
have included as supplemental material to this manu-
script the complete annotated sequence of each construct
(Additional file 1). The constructs, presented in order of
increasing length, are depicted in Figure 1 and were gener-
ated as follows:
hDAT
The pRC/CMV plasmid (Invitrogen, Carlsbad, California,
USA) containing the DAT1 coding region was obtained
(courtesy of Dr. Marc Caron, Duke University) and the
insert released via digestion with PmeI (New England
Biolabs, Beverly, MA, USA). The resultant fragments were
electrophoretically resolved on 1.5% agarose and the
band containing the DAT1  coding region was purified
using the QIAquick Gel Extraction Kit (Qiagen, Venlo, The
Netherlands). Similarly, pcDNA5/FRT was digested with
PmeI, the vector backbone purified (QIAquick PCR Puri-
fication Kit) and treated with shrimp alkaline phos-
phatase. The DAT1 insert underwent blunt end ligation
into the pcDNA5/FRT backbone by overnight reaction at
14°C with T4 DNA ligase (New England Biolabs).
hDAT Zero
An ~800 bp segment of the DAT1  3'UTR beginning
upstream of the stop codon and terminating proximal to
the VNTR element was cloned from banked human DNA
into pCR 2.1 TOPO using the TOPO TA Cloning Kit (Inv-
itrogen). Oligos DAT1E15F (5'-CAACCACAGTCTCGCG-
GCTTT-3') and DAT1E15ZeroR
(5'CTCAGGCCGTTCCCTACACC-3') were used in con-
junction with Platinum Pfx DNA Polymerase (Invitrogen)
to drive 35 cycles of PCR using the manufacturer's recom-
mended protocol. Following initial amplification, 1 U of
Taq polymerase was added to the reaction mixture and
incubated at 72°C for 10 minutes; the resultant PCR prod-
uct with 3' A-overhangs was used immediately in a TOPO-
TA cloning reaction. After transforming competent bacte-
ria and identifying clones containing the insert of interest,
the fragment containing the 3'UTR was released via
restriction digestion with BsmBI and XbaI (New England
Biolabs), band purified, and cloned into a BsmBI/XbaI
site in the pRC/CMV plasmid immediately downstream of
the DAT1 coding region. The resultant clone contained an
insert consisting of the DAT1 coding region flanked by a
~800 bp fragment of the 3'UTR up to, but not including,
the VNTR region. This construct was subcloned into the
pcDNA5/FRT plasmid via the same blunt end cloning
method used in the generation of the hDAT plasmid.
hDAT9 and hDAT10
The DAT1 15th exon from a previously genotyped 9/10
heterozygote was PCR amplified and cloned into pCR2.1-
TOPO using a protocol similar to that used in the genera-
tion of the hDAT Zero construct. Primers DAT1E15F
(sequence previously noted) and DAT1E15R (5'-
AGGGACCCACACGATGCTGA-3') were used to produce
a ~2100 bp PCR product that was subsequently made
TOPO-TA compatible through the previously described A-
overhang procedure. TOPO-TA reactions were immedi-
ately performed and used to transform competent bacte-
ria. Ampicillin-resistant bacterial colonies were isolated
and grown overnight using standard culture conditions.
Plasmid DNA was isolated and genotyped to differentiate
those containing the 9-repeat versus the 10-repeat VNTR
via a protocol that has been previously described [4]. Fol-
lowing identification of clones containing the 9 and 10
repeat VNTRs, respectively, the insert containing the entire
3'UTR was released via restriction digestion with BsmBI
and XbaI. The band was purified via gel extraction and
cloned into a BsmBI/XbaI site in the original pRC/CMV
plasmid. The resultant clones contained an insert consist-
ing of the DAT1 coding region flanked by a ~1900 bp frag-
ment of the 3'UTR harboring either the 9 or 10 repeat
variant. The insert was subcloned into the pcDNA5/FRT
plasmid via the previously described protocol.
Creation and maintenance of stably transfected model cell 
system
The Flp-In 293 host cell line (Invitrogen), an HEK-293
variant containing a Flp-In recombination site at a tran-
scriptionally active locus, was grown in complete medium
(D-MEM with 2 mM L-glutamine, 10% FBS, 1% penn/
strep) supplemented with 100 µg/mL Zeocin in a 37°C
incubator with 5% CO2. 48-hours prior to transfection,
cells were split into 6-well plates and grown to ~80% con-
fluence on the day of transfection and incubated in com-
plete medium lacking Zeocin. Cells were co-transfected
with one of the four DAT1 variants and pOG44 (Invitro-
gen), a plasmid encoding the Flp-recombinase enzyme
necessary for targeted stable integration [51]. The Lipo-
fectamine 2000 reagent was used to transfect the cells
according to the manufacturer's recommended protocol
(Invitrogen). Briefly, 3.6 µg pOG44 and 0.4 µg of one of
the four DAT1 constructs were diluted to a 250 µl volume
in Opti-MEM reduced serum media (Invitrogen); simi-
larly, 10 µL Lipofectamine 2000 was diluted to a volume
of 250 µL and incubated at room temperature for 5 min-
utes. The diluted DNA and Lipofectamine solutions were
combined and incubated at room temperature for 20
minutes and then added to culture medium. 24-hours
after transfection, cells were washed with PBS and fresh
complete medium was again added. 48-hours after trans-
fection, cells were split into fresh medium, plated on 150
mm × 25 mm cell culture dishes, and incubated at 37°C
until cells attached. Medium was then removed and
replaced with complete medium supplemented with the
selecting antibiotic hygromycin (100 µg/mL). SelectiveBMC Genetics 2005, 6:55 http://www.biomedcentral.com/1471-2156/6/55
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media was replaced every 4 days until hygromycin-resist-
ant foci were identified. Single resistant colonies were
encircled with a cloning cylinder, dislodged with 0.25%
trypsin, and expanded. Cells exhibiting the phenotype for
proper Flp-In recombination and demonstrating the pres-
ence of a cocaine-sensitive DAT as assessed by a rapid sin-
gle concentration [3H] dopamine uptake assay were
selected; clones were expanded to confluence in 2-tray
(1264 cm2) Nunc Cell Factories (Nalge Nunc Interna-
tional, Rochester, NY, USA). Once confluent, the four cell
lines were harvested with 37°C PBS containing 0.53
mmol/L ethylenediaminetetraacetic acid, separated into
aliquots, and centrifuged at 2000 × g for 10 min. Superna-
tants were decanted and the pellets were rinsed with 37°C
PBS. Pellets were again centrifuged at 2000 × g for 10 min,
the supernatants decanted, and the pellets stored at -80°C
until the time of assay. Mock transfected cells were con-
firmed to have no specific DAT binding or immunoreac-
tivity prior to initiation of assays.
General radioligand binding methods
Binding assays were carried out in 0.03 M phosphate
buffer (pH 7.4) containing 0.32 M sucrose. Membrane
suspensions were prepared by resuspending the pellet in
7 mL of ice cold assay buffer followed by homogenization
with a Polytron PT3000 for 20 seconds at 20,000 rpm. All
assays were performed in 12 × 75 mm polystyrene tubes
in a 1,000 µL final volume consisting of 800 µL of assay
buffer, 100 µL of [3H] Win 35,428 (Perkin Elmer, Boston,
MA), and 100 µL of cell membrane suspension. Competi-
tion assays were performed in a final volume of 1,000 µl
consisting of 700 µl assay buffer, 100 µL of [3H] Win
35,428, 100 µL of methylphenidate HCl (10-10 to 10-6 M)
(Sigma-Aldrich, St. Louis, MO), and 100 µl of cell suspen-
sion. Nonspecific binding was defined via the addition of
25 µM cocaine HCl (Sigma-Aldrich). Incubations were
terminated via rapid vacuum filtration through GF/B fil-
ters presoaked in assay buffer containing 0.3% polyethyl-
eneimine and rinsed with three washes (5 mL) of ice cold
assay buffer. Filters were punched, placed in scintillation
vials, and equilibrated overnight in 6 mL of liquid scintil-
lation cocktail (Ultima Gold, Packard, Meriden, CT, USA).
Vials were shaken and radioactivity determined in a liquid
scintillation counter at 50% efficiency for 240 sec/vial.
Saturation binding assays
The DAT radioligand [3H] Win 35,428 was isotopically
diluted with freshly weighed cold ligand (courtesy of Dr.
Michael Kuhar, Emory University) in silanized borosili-
cate glass tubes. Drug was initially dissolved in assay
buffer containing 5 mmol/L HCl at a concentration of 1
µg/µL followed by serial dilution with assay buffer. Satu-
ration binding assays utilized final [3H] Win 35,428 con-
centrations over a range of 0.5 to 75 nM. Total and
nonspecific binding was determined in triplicate at each
concentration of ligand. Assays were initiated by the addi-
tion of membrane suspension and incubated at 4°C for 4
hours.
Competition binding assays
[3H] Win 35,428 was isotopically diluted with freshly
weighed cold ligand in silanized borosilicate glass tubes
as previously described. The concentration used in com-
petition assays (5.85 nM) approximated the mean Kd for
[3H] Win 35,428 binding to the DAT from the binding site
saturation studies. Methylphenidate was dissolved in
assay buffer containing 5 mmol/L HCl at an initial con-
centration of 1 µg/µl. The concentrated solution subse-
quently underwent serial dilution to generate final
concentrations of competing ligand ranging from 0.01 to
10,000 nM. Assays were initiated by the addition of mem-
brane suspension, and incubated at 25°C for 1 hour.
Protein assays
At the time of each saturation binding assay, twelve 100
µL aliquots of each membrane homogenate were col-
lected for purposes of measuring total mean protein con-
tent with a BCA protein assay (Pierce Biotechnology,
Rockford, IL, USA). Protein assay results were used in the
normalization of saturation binding data to account for
minor differences in total added tissue.
Western blots
Cell pellets were homogenized in PBS in the presence of
DNAse and protease inhibitors (Roche Applied Science,
Indianapolis, IN, USA). Samples were then enzymatically
deglycosylated (Enzymatic Protein Deglycosylation Kit,
Sigma-Aldrich) prior to the loading and electrophoretic
resolution of 20 µg total protein in sample buffer (40 mM
Tris, pH 6.8, 0.1% SDS, 10% glycerol, 0.025% Bromphe-
nol blue) on 10% acrylamide. DAT, a highly glycosylated
protein, typically runs as a smear of high molecular weight
bands; deglycosylation reduces the core protein to a mass
of ~50 kD and greatly aids densitometry analysis. An
example of mature, fully-glycosylated DAT and the result-
ant high molecular weight smear is included as supple-
mental material (Additional file 2) to demonstrate the
significant benefit of sample deglycosylation. BioRad's
Precision Plus Protein Standards (Hercules, CA, USA)
were loaded into the first lane of each gel. Gels were trans-
ferred to PVDF membranes (Millipore, Billerica, MA,
USA) overnight at 3 mA. Membranes were blocked for 1
hour at RT (SuperBlock Blocking Buffer, Pierce Biotech-
nology) on an orbital shaker and probed with a rat anti-
DAT monoclonal antibody specific for the protein's N-ter-
minal region (1:250 dilution, courtesy Dr. Allan Levey,
Emory University) and rabbit anti 14-3-3β polyclonal
antibody (1:500 dilution, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at room temperature for 1 hour.
Following rinsing, the blot was incubated with a 1:10,000BMC Genetics 2005, 6:55 http://www.biomedcentral.com/1471-2156/6/55
Page 9 of 11
(page number not for citation purposes)
dilution of both Alexa Fluor 680 conjugated anti-rat IgG
(Molecular Probes, Eugene, OR, USA) and IRDye-800
conjugated Anti-Rabbit IgG (Rockland Immunochemi-
cals, Gilbertsville, PA, USA) for 1 h at room temperature.
Blots were rinsed, dried and visualized using a LI-COR
Biosciences Odyssey Infrared imager (Lincoln, NE, USA).
The ubiquitously expressed 14-3-3β was used as a protein
loading control. Western analyses were conducted in trip-
licate.
Data analysis
Radioligand binding data
Saturation and competition binding curves were analyzed
by the iterative, non-linear, curve fitting program Prism
4.0 (GraphPAD Software, Inc., San Diege, CA). Values for
Kd, Bmax and  Ki are expressed as mean values ± S.E.M
(Table 1). A one-way ANOVA with a Holm-Sidak post-hoc
analysis was used to identify statistically significant differ-
ences between VNTR variants. The threshold for statistical
significance was set at p < 0.05.
Western blot analysis
Western blots underwent densitometric analysis using the
program ImageJ 1.33 u (National Institutes of Health,
Bethesda, Maryland, USA). The DAT signal was normal-
ized to the 14-3-3β signal within each lane (expressed in
arbitrary units), then subsequently examined for main
effects of DAT1 genotype via a one way ANOVA with a
Holm-Sidak post hoc comparison. The threshold for sta-
tistical significance was set at p < 0.05.
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